• Users Online: 380
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Comparison of circulating matrix metalloproteinase-2 levels in untreated acute myeloid leukemia patients with remission status


 Department of Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq

Correspondence Address:
Zena Safaa Al-Din Shooman,
Department of Pathology, College of Medicine, University of Baghdad, Baghdad
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijh.ijh_20_23

BACKGROUND: Matrix metalloproteinases (MMPs) are proteases responsible for cleaving and rebuilding connective tissue components and also affect early carcinogenesis events, tumor development, growth, and neovascularization. The study aimed to evaluate the level of MMP-2 in acute myeloid leukemia (AML) patients in comparison with that in remission status, and healthy subjects, and to find its correlation with hematologic parameters. PATIENTS, MATERIALS, AND METHODS: This study included sixty newly diagnosed AML patients. Remission status was assessed after induction chemotherapy. The overall survival (OS) was determined after 6 months. The plasma MMP-2 level was measured at diagnosis by enzyme immunoassay. Twenty-eight healthy individuals were recruited as a control group. RESULTS: Plasma MMP-2 was higher in AML patients than in healthy individuals (P = 0.005). The level of MMP-2 was much higher in the M5 subtype than in the other subtypes (P = 0.0001). There was no statistically significant difference in the level of MMP-2 between patients who achieved complete remission and those who did not (P = 0.113). After 6 months, no significant difference in the initial MMP-2 levels was found between deceased and alive patients (P = 0.174). A positive correlation of MMP-2 level was found with white blood cell (WBC) count and hemoglobin (P = 0.0001 and 0.033, respectively) while insignificant with age, platelet count, and blast counts. CONCLUSIONS: The high MMP-2 level in AML patients suggests a possible role in the pathogenesis. However, it does not show any association with remission status or OS. The elevation was significantly associated with marrow monocytosis (M5) and correlated with a higher WBC count.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Shooman ZS
    -  Al-Rubaie HA
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed131    
    PDF Downloaded2    

Recommend this journal